The European Commission has granted a fifteen-month extension to the EU-funded RBDCOV project, extending the journey to August 31, 2025. This extra time is crucial for achieving the goals in testing the BIMERVAX® COVID-19 vaccine’s efficacy, tolerability, and safety in children and adolescents.
Progress with Adolescent Trials (Aged 12-17):
- Study Launched: May 2023
- Current Participants: 240 volunteers
- Target: 300 volunteers
- New Centres: CAP de Peralada in Girona and CAP de Centelles in Barcelona
Upcoming Trials for Children (Aged 5-11):
- HH-6 Study: Following HH-3, will explore optimal dosages and evaluate the immune response over a year.
- Goal: To confirm positive preliminary results from the adolescent study.
Earlier Phases:
- Focus: Adults with immunocompromising conditions.
- Participants: 240 volunteers with conditions like chronic kidney disease, primary immunodeficiencies, HIV, and autoimmune diseases.
Asphalion is proud to be the regulatory partner throughout the project, supporting every step to ensure the success of the RBDCOV project.
Have a look at the press release HERE
For further information, contact us at: [email protected]
